In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Opus Genetics Inc (NASDAQ: IRD) was $0.98 for the day, down -4.25% from the previous closing price of $1.02. In other words, the price has decreased by -$4.25 from its previous closing price. On the day, 0.78 million shares were traded. IRD stock price reached its highest trading level at $1.03 during the session, while it also had its lowest trading level at $0.9701.
Ratios:
Our analysis of IRD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 3.72 whereas as Long-Term Debt/Eq ratio is at 3.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on April 11, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 26 ’24 when Magrath George bought 100,000 shares for $0.98 per share. The transaction valued at 97,600 led to the insider holds 599,150 shares of the business.
YERXA BENJAMIN R bought 10,000 shares of IRD for $9,834 on Nov 21 ’24. The President now owns 342,800 shares after completing the transaction at $0.98 per share. On Nov 15 ’24, another insider, Magrath George, who serves as the Chief Executive Officer of the company, bought 90,294 shares for $1.01 each. As a result, the insider paid 91,215 and bolstered with 483,244 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRD now has a Market Capitalization of 58265128 and an Enterprise Value of 35315124. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 8.76. Its current Enterprise Value per Revenue stands at 2.587 whereas that against EBITDA is -0.974.
Stock Price History:
The Beta on a monthly basis for IRD is -0.00, which has changed by -0.3836478 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, IRD has reached a high of $2.18, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 3.07%, while the 200-Day Moving Average is calculated to be -9.92%.
Shares Statistics:
IRD traded an average of 1.03M shares per day over the past three months and 1214470 shares per day over the past ten days. A total of 45.48M shares are outstanding, with a floating share count of 29.40M. Insiders hold about 50.72% of the company’s shares, while institutions hold 22.78% stake in the company. Shares short for IRD as of 1749772800 were 489684 with a Short Ratio of 0.47, compared to 1747267200 on 233621. Therefore, it implies a Short% of Shares Outstanding of 489684 and a Short% of Float of 0.86.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Opus Genetics Inc (IRD) reflects the combined expertise of 1.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.26 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$1.09 and -$1.09 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$0.73, with 1.0 analysts recommending between -$0.73 and -$0.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $4.5M to a low estimate of $4M. As of the current estimate, Opus Genetics Inc’s year-ago sales were $1.11MFor the next quarter, 3 analysts are estimating revenue of $4.33M. There is a high estimate of $4.6M for the next quarter, whereas the lowest estimate is $4M.
A total of 3 analysts have provided revenue estimates for IRD’s current fiscal year. The highest revenue estimate was $18.3M, while the lowest revenue estimate was $16.37M, resulting in an average revenue estimate of $17.32M. In the same quarter a year ago, actual revenue was $10.99MBased on 4 analysts’ estimates, the company’s revenue will be $21.25M in the next fiscal year. The high estimate is $30M and the low estimate is $5M.
